PIK3CA and breast carcinoma: Using a mouse model of HER2-overexpressing (HER2+), PIK3CA (H1047R)-mutant breast cancer, PIK3CA (H1047R) enhances HER2-mediated breast epithelial transformation and metastatic progression, which develops trastuzumab resistance [16].